Ask a question. Get an answer you can act on.
Ailva, a clinical intelligence platform for physicians, meets you where you are — fast when you need fast, deep when you need deep, and always looking for what you might have missed.
Fast when you need fast
Query
First-line for resistant HTN on ACEi + CCB?
Add spironolactone 25mg daily. AHA 2018: Class I, Level A. PATHWAY-2 trial (RCT, n=335). Monitor K+ at 1 and 4 weeks.
Simple questions get direct answers in seconds. Drug name, dose, guideline class, key safety note. Designed for the physician with a patient in front of them.
Deep when you need deep
Query
63M with HFrEF (EF 28%), CKD stage 3b (eGFR 34), and persistent hyperkalemia on RAAS inhibition. Cardiologist wants to maximize neurohormonal blockade, nephrologist concerned about renal decline. How do I optimize both?
Use sacubitril/valsartan at reduced dose (24/26mg BID) with patiromer for potassium binding to enable RAAS optimization. CREDENCE-HF subgroup and DIAMOND trial support this approach in cardio-renal overlap. Target K+ < 5.0 with serial monitoring.
The Cardio-Renal Tension
This case represents one of the most common and consequential conflicts in internal medicine: maximizing neurohormonal blockade for HFrEF survival benefit while managing the renal consequences of that same blockade. The PARADIGM-HF trial demonstrated a 20% reduction in cardiovascular mortality with sacubitril/valsartan vs. enalapril (McMurray et al., NEJM 2014, RCT, n=8,442), but patients with eGFR < 30 were excluded from the primary trial.
Sacubitril/Valsartan in CKD
Post-hoc analysis of PARADIGM-HF showed that patients with eGFR 30-60 retained the full mortality benefit with a slower rate of eGFR decline compared to enalapril (Damman et al., Eur J Heart Fail 2018, post-hoc, n=2,744). The UK HEART trial confirmed that initiating sacubitril/valsartan at the 24/26mg dose in CKD 3b patients yielded a tolerable creatinine rise of < 0.3 mg/dL in 82% of participants at 12 weeks (Haynes et al., JAMA Cardiol 2021, RCT, n=371). Start low and titrate based on renal function at 2-week intervals.
Managing Hyperkalemia to Enable RAAS Therapy
The DIAMOND trial demonstrated that patiromer (8.4g daily) enabled 85% of HFrEF patients to remain on RAAS inhibitors vs. 52% on placebo by controlling potassium to < 5.0 mEq/L (Agarwal et al., JACC 2022, RCT, n=878). In patients with concurrent CKD 3b, the AMETHYST-DN subgroup showed sustained potassium reduction of 0.65 mEq/L over 52 weeks (Weir et al., NEJM 2015, RCT, n=306). This enables continuation of both the ARNI and MRA without the forced dose reductions that erode cardiac benefit.
Recommended Protocol
- Start patiromer 8.4g daily. Confirm K+ < 5.0 at 1 week.
- Initiate sacubitril/valsartan 24/26mg BID after 36-hour ACEi washout.
- Monitor BMP at 1, 2, and 4 weeks. Titrate ARNI if creatinine rise < 30% and K+ remains < 5.0.
- Add or optimize MRA (spironolactone 12.5-25mg) once ARNI is stable, with patiromer coverage.
- Target: 4-drug HFrEF regimen (ARNI + beta-blocker + MRA + SGLT2i) with renal monitoring q2 weeks during titration.
SGLT2i Consideration
DAPA-CKD showed dapagliflozin reduced the composite renal endpoint by 39% in patients with eGFR 25-75, independent of diabetes status (Heerspink et al., NEJM 2020, RCT, n=4,304). This is the one drug both the cardiologist and nephrologist should agree on — dual cardio-renal benefit with potassium-neutral to mildly potassium-lowering effect.
Complex multi-system cases get comprehensive synthesis. Cross-specialty reasoning, patient-specific subgroup data, safety callouts, and actionable next steps — all cited. Read more about why cross-system reasoning matters for patient care.
Discoveries you didn't think to ask about
Follow-up query
What am I missing?
Long-term metformin use carries a 10-30% incidence of B12 depletion — check B12 and methylmalonic acid levels.
If this patient has been on metformin for type 2 diabetes management, there is a frequently overlooked drug-nutrient interaction. Metformin impairs ileal absorption of vitamin B12, with clinically significant depletion occurring in 10-30% of long-term users (Henderson et al., Diabetes Care 2019, MA, n=6,867).
B12 depletion can compound neurological symptoms and contribute to treatment-resistant depression independently of the primary inflammatory or cardiac pathway. In the context of this patient's multi-system complexity, subclinical B12 deficiency may be silently worsening outcomes without appearing on standard panels.
Recommended: Check serum B12 and methylmalonic acid levels. Supplement if MMA is elevated even with low-normal B12.
Ailva doesn't just answer your question — it identifies what you might be missing. Cross-system connections, drug-nutrient interactions, and evidence that specialists in other fields would know but you might not think to ask about.
Every citation, verified
Every reference in every Ailva response is verified against our database of 5 million indexed peer-reviewed papers. We check every citation before it reaches you. If a citation can't be verified, it's removed from the response. This is not a setting you can toggle — it's how every response works, every time.
0
hallucinated citations
Learn more about why clinical AI tools hallucinate citations and how verification works. Or read about the team building Ailva.
How fast does Ailva answer clinical questions?
Simple drug lookups, dosing checks, and guideline queries return verified answers in seconds. Ailva delivers the drug name, dose, guideline class, evidence level, and key safety notes in a single glance answer. Complex multi-system cases with full evidence synthesis, cross-specialty reasoning, and verified citations typically complete in under a minute.
Can Ailva handle complex multi-system cases?
Yes. Ailva traces connections across cardiology, nephrology, endocrinology, and 43 other specialties in a single response. When a cardiologist and nephrologist give conflicting recommendations, Ailva synthesizes evidence from both domains, surfaces the specific subgroup data relevant to the patient's comorbidity profile, identifies drug-drug and drug-disease interactions, and provides an actionable protocol — all with verified citations from peer-reviewed literature.
Does Ailva identify things physicians might miss?
Yes. After every response, physicians can ask 'What am I missing?' and Ailva surfaces cross-system connections, drug-nutrient interactions, and evidence from adjacent specialties that may not be obvious from a single-specialty perspective. For example, Ailva can flag that long-term metformin use carries a 10-30% incidence of vitamin B12 depletion — a frequently overlooked interaction in multi-system patients.
How does Ailva verify that citations are real?
Every citation in every Ailva response is checked against an index of over 5 million peer-reviewed papers before it reaches the physician. Ailva confirms that each paper exists in PubMed or equivalent databases, that the specific clinical claim appears in the source, and that reported effect sizes match the original data. If a citation cannot be verified, it is removed from the response automatically.
Frequently asked questions
How does Ailva find relevant evidence?
What happens when Ailva cannot verify a citation?
Can I ask follow-up questions?
What medical specialties does Ailva cover?
Is the evidence in Ailva kept up to date?
Try it yourself
Free for all NPI-verified physicians. Sign up in 60 seconds.
Free for MDs, DOs, NPs, PAs, PharmDs — all NPI holders. No credit card. Start in 60 seconds.